Now that large language models like OpenAI’s ChatGPT and Google DeepMind’s Gemini have mainstreamed generative AI, several of the world’s most powerful tech companies are looking to biotech as the next frontier in artificial intelligence. At Nvidia, the bulk of investments at the company’s venture capital arm over the past two years have been in drug discovery. At DeepMind, the Google AI lab’s AlphaFold model — a groundbreaking tool for predicting protein structures — has been used by academic researchers over the past year to develop a "molecular" syringe to inject medicine directly into cells. Microsoft, Amazon, and even Salesforce have protein design projects as well. Since 2021, there have been 281 venture capital deals worldwide in AI drug discovery startups, accounting for $7.7 billion in investment, according to Pitchbook. The computer-aided drug discovery industry could build the next trillion-dollar drug company. That is why these companies are investing so heavily.